DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for exudative vitreoretinopathy 4 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleExudative vitreoretinopathy 4 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for exudative vitreoretinopathy 4 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
In a 2012 study of six patients with retinal detachment and inferior proliferative vitreoretinopathy grade 3, treatment with pars plana vitrectomy and Densiron tamponade achieved retinal re-attachment without further tamponade in five patients; one patient required additional conventional silicone oil. Mean visual acuity improved from 29.2 ETDRS letters preoperatively to 50.2 letters four to six weeks after Densiron removal. Elevated intraocular pressure during tamponade was the most common complication and resolved after removal. The sample is six patients, no control group, and follow-up was short.
A 2025 report on a family with a novel VCAN variant (c.4004-2A>C) describes two sisters aged 16 and 18 and their 48-year-old father, all with vitreoretinal ring opacities, traction, peripheral pigmentary clumps, lattice-like features, retinoschisis, foveal ectopia, and nasal vessel displacement. Imaging showed regions of inner retinal thinning with spared outer retina, likely from vitreoretinal traction, alongside large areas of photoreceptor degeneration with normal or thickened inner retina. This is a single-family report with three patients, no treatment intervention, and no functional outcome data.
A 2009 review summarises the cell biology and molecular mediators of proliferative vitreoretinopathy but provides no original patient data, no specific drug or intervention results, and no quantitative outcomes.
What is still missing: no randomised controlled trial for any drug in exudative vitreoretinopathy 4; no validated animal model that recapitulates the human VCAN variant phenotype; no funding for a multi-centre natural history study that could define endpoints for future trials; no stratification by genetic subtype or by traction versus degenerative mechanisms.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Seminars in Ophthalmology · 2009 · 52 citations
Proliferative Vitreoretinopathy: Pathobiology and Therapeutic Targets
AbstractThe cell biology and molecular mediators of proliferative vitreoretinopathy continue to be elucidated. The purpose of this review is to summarize contemporary findings in the visual and neurosciences relevant to the pathophysiology of proliferative vitreoretinopathy, with an emphasis on the biologic mediators that represent potential therapeutic targets.
Klinische Monatsblätter für Augenheilkunde · 2012 · 2 citations
Schwere Tamponade bei komplizierten inferioren Netzhautablösungen
AbstractBACKGROUND: Retinal detachment with inferior proliferative vitreoretinopathy is a difficult to treat problem. The aim of our study was to assess the safety and efficacy of Densiron in the clinical management of complicated retinal detachment. HISTORY AND SIGNS: 6 eyes of 6 consecutive patients presenting with a retinal detachment with inferior proliferative vitreoretinopathy grade 3 were treated with pars plana vitrectomy and injection of Densiron. The mean age of the patients was 61 years. 3 patients had a previous unsuccessful vitreoretinal surgery and 3 patients had Densiron as a first procedure. The extent of detachment was at least 2 or more quadrants with macular involvement in 3 cases. Preoperatively the mean visual acuity was 29.2 letters with ETDRS. THERAPY AND OUTCOME: Densiron was removed after an average of 58 days. 5 patients achieved retinal re-attachment without further tamponade, and 1 patient after additional injection of conventional silicon oil. 4 - 6 weeks after removal of Densiron the mean visual acuity was 50.2 letters with ETDRS. The most common complication was an elevated intraocular pressure during endotamponade, which resolved following removal of the agent. CONCLUSIONS: Densiron improves inferior tamponade, and in clinical practice may be considered to increase the anatomic success rate in selected cases of complicated retinal detachment with inferior proliferative vitreoretinopathy.
Detailed structural abnormalities associated with a novel <i>VCAN</i> variant in a family with versican vitreoretinopathy
AbstractPurpose To understand the retina micropathology in a family with a novel variant in VCAN.Methods Two sisters ages 16 (proband) and 18 years old and their 48-year-old father underwent comprehensive ophthalmic evaluations. Multimodal imaging was performed with spectral domain optical coherence tomography, ultrawide field short-wavelength fundus autofluorescence, and pseudocolor imaging.Results Cataracts were present in the sisters along with a penetrant retinal phenotype in all three patients with vitreoretinal ring opacities and traction, peripheral pigmentary clumps, lattice-like features, retinoschisis, foveal ectopia, and nasal displacement of vessels. There were regions with inner retinal thinning with spared outer retina, likely a consequence of vitreoretinal traction, that contrasted with large areas of profound photoreceptor degeneration, but with a rather normal or thickened inner retina. A previously unreported heterozygous variant in intron 7 of VCAN (c.4004-2A>C) segregated with the phenotype in the proband and her father.Conclusions Segregation of a versican-associated vitreoretinopathy supports the pathogenicity of the VCAN variant. The patterns of structural abnormalities support classical mechanisms of disease that involve local vitreoretinal traction, as well as possible alternative developmental and/or degenerative changes of the retina, RPE, and/or choroid that result from the primary molecular defect.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
